Valneva SE is a French specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. The company focuses on travel and public health vaccines, marketing commercial products such as IXIARO for Japanese encephalitis, DUKORAL for cholera, and IXCHIQ for chikungunya. Valneva leverages proprietary technologies, including its EB66 cell-line platform, to support end-to-end vaccine development and manufacturing. The company operates manufacturing facilities in Scotland, Sweden, and Austria, alongside commercial and R&D offices across Europe and North America. In addition to its marketed portfolio, Valneva advances a clinical pipeline targeting diseases with significant unmet medical needs, including Lyme disease, Shigella, and Zika virus. The company frequently collaborates with major pharmaceutical partners to support late-stage clinical trials and global commercialization efforts.
